Printer Friendly

Exelixis, Ipsen initiate Phase 3 COSMIC-312 trial.

Exelixis (EXEL) and Ipsen (IPSEY) announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib versus sorafenib in previously untreated advanced hepatocellular carcinomaThe co-primary endpoints of the trial are progression-free survival and overall survival. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting. COSMIC-312 is a multicenter, randomized, controlled phase 3 pivotal trial that aims to enroll approximately 640 patients at up to 200 sites globally. Patients will be randomized 6:3:1 to one of three arms: cabozantinib and atezolizumab, sorafenib, or cabozantinib. Exelixis is sponsoring COSMIC-312, and Ipsen will co-fund the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Genentech, a member of the Roche Group, is providing atezolizumab for use in this trial.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Dec 5, 2018
Words:134
Previous Article:Genentech granted priority review for Tencentriq, chemotherapy combination.
Next Article:U.S. Silica announces price increases on industrial and specialty products.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |